FRAUD IN THE DEVELOPMENT OF LUPRON? by David Redwine (reprinted) (Lupron is the main puberty blocker used in precocious puberty and gender affirming care-transgendered kids) Here is the core of the issue: during early (1980's) development of Lupron for the treatment of endometriosis, TAP (Takeda/Abbott Pharmaceuticals) developed information that by one year after stopping Lupron, ovarian function did not return to baseline in most (63%) of the few patients followed that long. This apparent damage to ovarian function long after Lupron was discontinued was hidden from physicians and patients and was revisited by the manufacturer only one time using fabricated evidence. Fast-forward to a 2018 medical publication which reported that 45% of patients who took Lupron as teenagers and who answered a questionnaire 4 or more years after stopping Lupron complained of symptoms suggestive of ovarian dysfunction that they considered to be irreversible and due to Lupron. This is consistent with what the manufacturer knew but kept hidden. How could this later paper not be related to the hidden findings regarding ovarian dysfunction identified over 30 years ago? This means that no patient has ever received proper informed consent before agreeing to Lupron therapy.
FRAUD IN THE DEVELOPMENT OF LUPRON
Please let this law firm know: https://www.girardsharp.com/work-investigations-puberty-blockers